Home » Newsletters » BioWorld Science

BioWorld Science

June 4, 2015

View Archived Issues

Dual GHSR-NPY2R targeting peptides show promise for obesity treatment

QPCT: new druggable target for Huntington's disease identified by siRNA screen

Novira Therapeutics divulges anti-HBV azepanes

Biotest and Affibody sign Albumod research license and option agreement

Ontario Institute for Cancer Research invests in PanCuRx pancreatic cancer initiative

HTG Molecular Diagnostics and MD Anderson to investigate molecular diagnostics for lung cancer

German Centre for Infection Research announces clinical investigation of anti-MRSA

Phase I results reported for the small-molecule glutaminase inhibitor CB-839

NeoStem to change name to Caladrius Biosciences

Vitesse Biologics created by Baxter Ventures, Mayo Clinic and Velocity Pharmaceutical Development

ProLynx cleared to start phase I trial of PEG-SN-38

Oncolytic virus therapy with recombinant HSV-1 is efficient for NSGCT treatment

EMA provides guidance on MAA submission for Locilex

Nektar and MD Anderson Cancer Center to collaborate on phase I/II trials of NKTR-214

Amgen to collaborate with Roche on phase Ib study of talimogene laherparepvec with atezolizumab

Neovia Oncology and FDA meet to discuss NEV-801 IND

RaQualia to begin first-in-human phase I study of RQ-00310941

Wistar Institute patents EBNA-1 inhibitors

Catabasis Pharmaceuticals discloses PCSK9 inhibitors

Pfizer presents EGFR inhibitors

European Commission approves Akynzeo

NICE recommends Vargatef for NSCLC in England and Wales

FDA awards orphan drug designation to ibudilast for Krabbe disease

Amicus submits MAA seeking full European approval of Galafold for Fabry's disease

FDA issues letter of support for autosomal dominant polycystic kidney disease biomarker

Genzyme's olipudase alfa granted FDA breakthrough therapy designation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...